Solid Tumors (Phase 1) clinical trials

TX103 CAR-T cells for advanced solid tumors

This trial tests a new treatment called TX103 CAR-T cells for people with advanced solid tumors that have a specific protein (B7-H3). The goal is to see if these modified immune cells can shrink tumors or slow their growth.

A study of BHV-1530 for advanced solid tumors

This trial tests a new drug, BHV-1530, either alone or with another drug called cemiplimab, for people with certain advanced solid tumors that have stopped responding to standard treatments. The goal is to see if it's safe and effective.

LB1410 and LB4330 for advanced solid tumors

This trial tests a combination of two experimental drugs (LB1410 and LB4330) in people with advanced or metastatic solid tumors that have stopped responding to standard treatments or where no standard treatment exists. It aims to see if this combination can shrink tumors or slow their growth.

Study of RPTR-1-201 for advanced solid tumors

This trial tests a new drug called RPTR-1-201 for people with advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and effective.

CEL001 injection safety study for advanced solid tumors

This trial tests a new injection called CEL001 for people with advanced solid tumors that have not responded to or cannot tolerate standard treatments. The goal is to see if it is safe and find the right dose.

Testing DR30206 for advanced or metastatic solid tumors

This trial tests a new drug called DR30206 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and how the body processes it.

A Phase I/IIa Study of SYS6041 in Patients With Advanced Solid Tumors

Testing SKB571 for advanced solid tumors

This study tests an experimental drug called SKB571 for people with advanced solid tumors that have not responded to or stopped responding to standard treatments. The goal is to see if SKB571 is safe and to find the right dose.

Testing DB-1419 for advanced solid tumors

This trial tests a new drug called DB-1419 for people with advanced solid tumors that have not responded to other treatments. It is designed to target a protein called B7-H3 on cancer cells, and may help shrink tumors or slow their growth.

ROSE12 alone and with other drugs for advanced solid tumors

This trial tests a new drug called ROSE12, given alone or with other cancer treatments, for people with advanced solid tumors that have not responded to standard therapies. The study aims to see if ROSE12 is safe and effective.

Personalized cancer vaccine trial for solid tumors

This trial tests a custom-made vaccine designed to train your immune system to fight your specific cancer. It may be an option if you have advanced cancer that stopped responding to treatment or early-stage cancer with a high risk of coming back.

A study of two drugs for KRAS G12D tumors

This trial tests two experimental drugs (IN10018 and RNK08954) together for people with advanced solid tumors that have a specific KRAS G12D mutation. The goal is to see if this combination can shrink tumors when standard treatments have stopped working.

Testing RC278 for Solid Tumors

This study tests a new drug called RC278 for people with solid tumors that have not spread to the brain. It aims to see if the drug is safe and effective, and may be an option for those who are otherwise fairly healthy.

Using lymph node T cells for advanced solid tumors

This trial tests a new treatment using T cells taken from your lymph nodes to fight advanced solid tumors that have not responded to standard therapies. The goal is to see if this approach can help shrink tumors or slow their growth.

Early trial of BL-M07D1 for advanced HER2-positive digestive tumors

This early-phase trial tests BL-M07D1 in people with advanced digestive tract (and other solid) cancers that can’t be removed with surgery and have already tried or can’t use standard treatment. It’s studying whether the drug works and how safe it is, and whether HER2 tumor results are linked to benefit.

Study of HDM2020 for advanced solid tumors

This trial is testing a new drug called HDM2020 for people with advanced solid tumors that have not responded to other treatments. The goal is to see if the drug is safe and how well it works.

Study of HY0001a for Advanced Solid Tumors

This trial tests a new drug, HY0001a, for people with advanced solid tumors that have not responded to standard treatments. The drug targets a protein on some cancer cells, and the study aims to find the right dose and see if it helps shrink tumors.

HRS-7058 plus other drugs for solid tumors

This trial tests a new drug called HRS-7058 combined with other anti-tumor medicines for people with solid tumors. The goal is to see if the combination is safe and effective. It might be an option if you have advanced cancer and have not responded to other treatments.

Study of GW5282 for advanced solid tumors

This trial tests a new oral drug, GW5282, for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if this drug can shrink tumors or stop them from growing.

Testing a new cancer immunotherapy in advanced solid tumors

This Phase 1 trial tests a new drug called IUAb190708 designed to help your immune system fight advanced or recurrent solid cancers. The study will evaluate its safety, how your body handles it, and whether it works against your tumor.

CKD-512 with or without pembrolizumab for advanced solid tumors

This trial tests a new drug, CKD-512, alone or combined with pembrolizumab, in people with advanced or metastatic solid tumors that have stopped responding to standard treatments. It aims to see if this therapy can help when other options are no longer working.

First-in-human study of HBT-708 for advanced solid tumors

This trial tests a new drug called HBT-708 for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if the drug is safe and how the body handles it.

Study of a new drug for advanced solid tumors after immunotherapy

This study tests a new drug called PLN-101095 in people with advanced solid tumors whose cancer has stopped responding to a common immunotherapy. The goal is to see if combining this new drug with pembrolizumab can help control the cancer again.

Study of ZE94-0605 for advanced solid tumors

This trial tests a new drug called ZE94-0605 for people with advanced solid tumors that haven't responded to standard treatments. The goal is to see if it is safe and can shrink tumors.